article thumbnail

Investment fuels AI-driven development of breakthrough genomic medicines

pharmaphorum

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 91
article thumbnail

New approach to diagnosing genetic diseases using RNA sequencing increases yield

Scienmag

In the world of rare genetic diseases, exome and genome sequencing are two powerful tools used to make a diagnosis. A recent addition to the toolkit, RNA sequencing, has been demonstrated to help researchers narrow down disease candidate variants identified first on exome and genome sequencing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UNH team finds repurposed drug hinders enzyme activity linked to Covid-19

Pharmaceutical Technology

Coronaviruses, like Covid-19, are a notorious group of infectious agents that include a large class of viruses with RNA genomes, similar to the human DNA genome, that depend on well-organised protein structures crucial for viral growth and replication.

Drugs 130
article thumbnail

Moderna partners with Life Edit for mRNA gene editing therapies

Pharmaceutical Technology

Moderna Genomics general manager and chief scientific officer Eric Huang said: “Through our collaboration with Life Edit, we hope to harness the power of gene editing technologies as part of our broader research and development engine, helping to advance our mission and deliver on the promise of mRNA.”

article thumbnail

Evox Therapeutics acquires exosome AAV technology from Codiak

Drug Discovery World

Evox Therapeutics has purchased Codiak Biosciences engEx-AAV technology platform, including all intellectual property rights, and exclusive access to certain engineering and manufacturing rights.

article thumbnail

Sanofi wagers $400m on miRecule muscular dystrophy therapy

pharmaphorum

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018.

RNA 93
article thumbnail

Boost for mRNA as Moderna to acquire OriCiro for $85 million

pharmaphorum

and OriCiro Genomics K.K. However, its messenger RNA (mRNA) platform – building on continuous advances in basic and applied mRNA science – permits the development of therapeutics and vaccines for other infectious diseases, immune-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases as well. Biotech Moderna, Inc.